KEVIN MADAYAG: Open Payments
NPI 1518477181 · SCOTTSDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,432 in 188 payments from 23 companies in 2025. Trend: 2023 $2,647 · 2024 $2,575 · 2025 $3,432
Food & beverage: $3,339Consulting: $93
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 50 | $657 |
| AstraZeneca Pharmaceuticals LP | 12 | $512 |
| GENZYME CORPORATION | 19 | $315 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $269 |
| CSL Behring | 9 | $248 |
| Organon LLC | 6 | $206 |
| Regeneron Healthcare Solutions, Inc. | 9 | $175 |
| Optinose US, Inc. | 12 | $154 |
| Amgen Inc. | 7 | $128 |
| Blueprint Medicines Corporation | 3 | $118 |
Products named: NUCALA, DUPIXENT, TEZSPIRE, VTAMA, TRELEGY ELLIPTA, AYVAKIT, CUVITRU, Xhance.
Industry payments across AZ — which companies pay providers there.
